Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 16/20 | 0.50 |
| ▸ | KIT | P10721 | 4/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21408138 | 0.90 | CSF1R (0.61) | CSF1RPDGFRAKITPDGFRBMET | |
| SCHEMBL30890847 | 0.90 | CSF1R (0.61) | CSF1RPDGFRAKITPDGFRBMET | |
| SCHEMBL21408137 | 0.83 | CSF1R (0.44) | CSF1RPDGFRAKITPDGFRBMET | |
| SCHEMBL21772029 | 0.80 | CSF1R (0.66) | CSF1RPDGFRAKITPDGFRBMET | |
| SCHEMBL21408136 | 0.74 | TGFBR1 (0.36) | CSF1RPDGFRAKITPDGFRBCYP2C9 | |
| SCHEMBL21408156 | 0.73 | TGFBR1 (0.37) | CSF1RPDGFRAPDGFRBMETCYP2C9 | |
| SCHEMBL30890842 | 0.71 | CSF1R (0.71) | CSF1RPDGFRAKITPDGFRBMET | |
| SCHEMBL21425677 | 0.71 | CSF1R (0.71) | CSF1RPDGFRAKITPDGFRBMET | |
| SCHEMBL21425516 | 0.71 | CSF1R (0.70) | CSF1RPDGFRAKITPDGFRBMET | |
| SCHEMBL22728930 | 0.70 | CSF1R (0.62) | CSF1RPDGFRAKITPDGFRBMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018214867-A9 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2019-10-03 | — | — | WO | disclosed |